Recently, Pudong Venture Capital Group was a participant in the successful completion of the A+++ round of financing for Shanghai Enkay Cell Technology Co., Ltd., also known as Enkay Therapeutics. This substantial funding will propel Enkay Therapeutics forward in the clinical trials of its core products and the development of new product pipelines, thus expediting the clinical translation of NK cell drugs. In recent years, the venture capital market has witnessed a surge in '+++' rounds and even more '+' rounds of financing, particularly in sectors such as semiconductors, biopharmaceuticals, embodied intelligence, and the low-altitude economy. The prolonged cycle of technological research and development, coupled with the need for commercialization verification, often poses challenges for startups in meeting the stringent requirements for the next round of financing. Consequently, many startups opt to extend their development cycles through multiple '+' rounds of financing. Simultaneously, as valuations in the primary market escalate, investment institutions, while exercising caution in their investments, are reluctant to pass up on promising projects. As a result, they adopt a strategy of "small steps, fast progress" to complete financing rounds.